Tuesday, 12 May 201508:00 | Registration | |
Session Chair: Charles Cox, Head Genetics Experiment Design and Delivery, GSK Pharmaceuticals |
| | 09:00 | Shaping Personalized Medicine through Partnerships
Cecilia Schott, Head Personalized Healthcare, Corporate Business Development Global Product & Portfolio Strategy, AstraZeneca, United States of America
The deeper understanding of the molecular mechanisms of diseases creates an intrinsic need for diagnostic tools that can predict a patient response to a drug treatment. As a result the reality of drug development is no longer a well known and established process followed by biopharmaceutical companies. The increasing speed of technology innovation associated with biomarker discovery is shaping drug development and creating new business models. When a diagnostic is co-developed with a drug to guide its therapy, the aim is that the drug and diagnostic will be incorporated in clinical practice at the same time. Biopharmaceutical companies need simultaneous access to a variety of selection tools that are not part of their core capabilities and can only be made available through partnerships. Bringing together two industries, biopharmaceutical and diagnostics, which have very different business strategies, requires flexibility and creativity to deliver better patient outcomes. | 09:45 |  | Keynote Presentation Personalised Breast Cancer Medicine
Carlos Caldas, Group Leader, Cancer Research UK, Cambridge Institute, United Kingdom
|
| 10:45 | Coffee and Networking | 11:15 | Blood-based Biomarker Assays for Personalised Tumour Therapy
Thomas Krahn, Head of Global Biomarker Research Department, Bayer Pharma Ag, Germany
Blood based biomarker for early diagnosis and patient stratification, detection of circulating tumour DNA in cancer patients and Isolation and molecular analysis of circulating tumour cells will be discussed in the presentation. | 12:00 | Clinical Implications of Intratumoral Heterogeneity in High Grade Serious Ovarian Cancer
James Brenton, Senior Group Leader, Cancer Research UK, United Kingdom
| 12:45 | Lunch and Networking | |
Session Chair: Iain Miller, European Personalized Medicine Association |
| | 14:15 | | 15:15 | Strategy of Sequencing the Whole Genome in Clinical Practice with Illumina X Ten
Jurgen Eils, Head, German Cancer Research Centre, Germany
Resources and infra-structure required for playing the leading role in clinical sequencing will be highlighted in this presentation. Furthermore the aspects of precision oncology and the relating IT challenges will be discussed. | 16:00 | Coffee and Networking | 16:30 | Pathway Illumination for Disease Research - Psychiatric Disorders and Antidepressant Treatment Response
Christoph Turck, Head, Max Planck Institute of Psychiatry, Germany
Biomarkers predicting a priori whether an individual patient will respond to the treatment of choice and an early distinction of responders and non-responders during antidepressant therapy can have a significant impact for realizing strategic treatment. | 17:15 | End of Day One |
Wednesday, 13 May 2015 |
Session Chair: Liz Harrington, Director of Translation Science, Astrazeneca |
| | 09:00 | “Big Data” – A Key to Personalized Medicine?
Andreas Schuppert, Vice President, Bayer Technology Services GmbH, Germany
In this presentation we demonstrate on a heterogeneous set of gene expression data from cancer studies, that integration of Big Data and mechanistic understanding of disease propagation provides a systematic approach for significant improvement of the reliability of model predictions. | 09:45 |  | Keynote Presentation Genomics England: The 100,000 Genomes Project
Mark Caulfield, Chief Scientist, Queen Mary University of London, United Kingdom
The 100,000 Genomes Project focusses on whole genome sequencing of rare inherited diseases, cancers and infections and will create a life-course resource for research and health. |
| 10:45 | Coffee and Networking | 11:15 | Integrated Genetics – The Advent of the $100 Genome to Support Clinical Studies
Charles Cox, Head Genetics Experiment Design and Delivery, GSK Pharmaceuticals, United Kingdom
| 12:00 | Personalized Medicine Patents – Opportunities and Challenges
Claudia Meinken, European Patent Attorney, Patents and Trademarks for Life Sciences, Germany
The presentation will provide an overview on patentable subject matter in connection with personalized medicine highlighting the challenges arising when it comes to the enforcement of personalized medicine patents. | 12:45 | Lunch and Networking | |
Session Chair: Claudia Meinken, European Patent Attorney, Patents and Trademarks for Life Sciences |
| | 14:00 | The Emerging Commercial Paradigm for Personalized Medicine: Recent Developments and EU Market Access
Iain Miller, Co-Founder, Healthcare Strategies Group, United Kingdom
In this presentation, Dr. Miller will discuss market access in the EU and UK, with a particular emphasis on technology review by NICE in the UK. He will also discuss some important recent developments in the field of PM, including immunotherapy stratification, regulatory and reimbursement trends. | 14:45 | Supporting Innovation in Companion Diagnostics: The Regulator’s View
Rosalind Polley, Senior Medical Device Specialist, Medicines & Healthcare Products Regulatory Agency (MHRA), United Kingdom
Background on current and future regulation of in vitro diagnostic devices in Europe as this relates to companion diagnostics used to determine treatment. | 15:05 | Coffee and Networking | 15:20 | Global Market Access for Companion Diagnostics
Kristin Ciriello Pothier, Partner & Managing Director/Life Sciences Leader, Ernst and Young LLP, United States of America
Scott Palmer, Vice President , Ernst & Young LLP, United States of America
This presentation will highlight the evolving landscape of companion diagnostics, with a focus on innovative marketing and partnering strategies. | 16:05 | Close of Conference |
|
Add to Calendar ▼2015-05-12 00:00:002015-05-13 00:00:00Europe/LondonPersonalised Medicine 2015Personalised Medicine 2015 in CambridgeCambridgeSELECTBIOenquiries@selectbiosciences.com
